Astrazeneca plc ADR (AZN) concluded trading on Wednesday at a closing price of $66.58, with 3.88 million shares of worth about $258.17 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -14.37% during that period and on January 08, 2025 the price saw a loss of about -0.09%. Currently the company’s common shares owned by public are about 3.10B shares, out of which, 3.10B shares are available for trading.
Stock saw a price change of 1.62% in past 5 days and over the past one month there was a price change of -2.38%. Year-to-date (YTD), AZN shares are showing a performance of 1.62% which decreased to -3.80% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $60.47 but also hit the highest price of $87.68 during that period. The average intraday trading volume for Astrazeneca plc ADR shares is 5.62 million. The stock is currently trading 0.50% above its 20-day simple moving average (SMA20), while that difference is down -0.33% for SMA50 and it goes to -11.14% lower than SMA200.
Astrazeneca plc ADR (NASDAQ: AZN) currently have 3.10B outstanding shares and institutions hold larger chunk of about 15.80% of that.
The stock has a current market capitalization of $206.44B and its 3Y-monthly beta is at 0.47. PE ratio of stock for trailing 12 months is 32.00, while it has posted earnings per share of $2.08 in the same period. Its PEG reads 2.88 and has Quick Ratio of 0.71 while making debt-to-equity ratio of 0.78. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AZN, volatility over the week remained 1.17% while standing at 1.35% over the month.
Stock’s fiscal year EPS is expected to rise by 13.60% while it is estimated to increase by 13.72% in next year. EPS is likely to shrink at an annualized rate of 11.12% for next 5-years, compared to annual growth of 17.72% made by the stock over the past 5-years.
On September 13, 2024, Deutsche Bank Downgrade their recommendations, while on May 30, 2024, Goldman Initiated their ratings for the stock with a price target of $97. Stock get a Hold rating from Deutsche Bank on April 16, 2024.
